Navigation Links
Gentiva® Health Services Schedules 2011 Outlook Conference Call and Webcast for Thursday, December 16, 2010
Date:12/3/2010

ATLANTA, Dec. 3, 2010 /PRNewswire-FirstCall/ -- Gentiva Health Services, Inc. (Nasdaq: GTIV), the nation's largest provider of home health and hospice services, announced today that it has scheduled a conference call and webcast on Thursday, December 16, 2010, at 10:00 a.m. ET to provide an update on its 2011 outlook. Gentiva plans to issue a news release the morning of December 16 before pre-market trading.

The December 16, 2010 conference call is open to investment analysts and managers, Company shareholders and others interested in Gentiva Health Services. Instructions for participation in the conference call follow:

  • Event: Gentiva Health Services' 2011 outlook conference call.

  • Date and Time: Thursday, December 16, 2010, 10:00 a.m. ET.

  • Instructions: Participants in the United States, Canada and international locations may call (973) 935-2408 and reference call #28911058.

  • Webcast URL: http://investors.gentiva.com/events.cfm.

  • Replay: A replay of the call will be available on December 16, beginning at approximately 1 p.m. ET, and will remain available continuously through December 23. To listen to a replay of the call from the United States, Canada or international locations, dial (800) 642-1687 or (706) 645-9291 and enter the following PIN at the prompt: 28911058. Visit http://investors.gentiva.com/events.cfm to access the webcast archive.

  • Transcript: A transcript of the call, including questions and answers, is expected to be available on Gentiva's website within 48 hours after its conclusion.

  • About Gentiva Health Services, Inc.Gentiva Health Services, Inc. is the nation's largest provider of home health and hospice services based on revenue, delivering innovative, high quality care to patients across the United States. Gentiva is a single source for skilled nursing; physical, occupational, speech and neurorehabilitation services; hospice services; social work; nutrition; disease management education; help with daily living activities; and other therapies and services. In August 2010, Gentiva acquired Odyssey HealthCare, Inc., one of the leading providers of hospice care in the United States. GTIV-E

    Forward-Looking StatementCertain statements contained in this news release, including, without limitation, statements containing the words "believes," "anticipates," "intends," "expects," "assumes," "trends" and similar expressions, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based upon the Company's current plans, expectations and projections about future events. However, such statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These factors include, among others, the following: economic and business conditions, including the ability to access capital markets; demographic changes; changes in, or failure to comply with, existing governmental regulations; the impact on our Company of recently passed healthcare reform legislation and its subsequent implementation through governmental regulations; changes in Medicare, Medicaid and commercial payer reimbursement levels; the outcome of any inquiries into the Company's operations and business practices by governmental authorities; the Company's ability to effectively integrate Odyssey's operations and those of other acquisitions we may make, as well as the ability to achieve expected synergies and efficiencies within expected time frames; effects of competition in the markets in which the Company operates; liability and other claims asserted against the Company; ability to attract and retain qualified personnel; availability and terms of capital; loss of significant contracts or reduction in revenues associated with major payer sources; ability of customers to pay for services; business disruption due to natural disasters, pandemic outbreaks, or terrorist acts; effect on liquidity of the Company's debt service requirements; and changes in estimates and judgments associated with critical accounting policies and estimates. For a detailed discussion of certain of these and other factors that could cause actual results to differ from those contained in this news release, please refer to the Company's various filings with the Securities and Exchange Commission (SEC), including the "Risk Factors" section contained in the Company's annual report on Form 10-K for the year ended January 3, 2010, as supplemented in the Company's quarterly report on Form 10-Q for the second quarter ended July 4, 2010.Financial and Investor Contact:
    Eric Slusser 770-951-6101eric.slusser@gentiva.comor John Mongelli770-221-6700john.mongelli@gentiva.comMedia Contact:Scott CianciulliBrainerd Communicators212-986-6667cianciulli@braincomm.com
    '/>"/>

    SOURCE Gentiva Health Services, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related biology technology :

    1. Crescent Healthcare Expands East Coast Presence
    2. HeartWare to Present at the 22nd Annual Piper Jaffray Health Care Conference
    3. Ridge Diagnostics, Inc. Presents Clinical Data on Blood Test for Depression at U.S. Psychiatric and Mental Health Congress
    4. Chimerix Presents Update on CMX001 Development to the World Health Organization Advisory Committee on Variola Virus Research
    5. The Israeli Governments Ministry of Health Invites Medisafe 1 Technologies to Demonstrate its Unique Syringe Locking Device Technology
    6. Keryx Biopharmaceuticals to Present at Lazard Capital Markets 7th Annual Healthcare Conference
    7. Intarcia Therapeutics Executive Chairman, Kurt Graves to Present at Lazard Capital Markets 7th Annual Healthcare Conference
    8. Argos Therapeutics to Present Corporate Overview and Next Steps in Clinical Development of Arcelis™ Immunotherapy at Lazard Capital Markets 7th Annual Healthcare Conference
    9. Accuray Incorporated to Speak at Seventh Annual Lazard Capital Markets Healthcare Conference
    10. Anadys Pharmaceuticals to Present at the Lazard Healthcare Conference
    11. Marshall Edwards CEO to Present at Lazard Capital Markets Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/16/2017)... 2017  ImMAGE Biotherapeutics (OTCMKTS: IMMG), an early-stage biotechnology company ... better treatment for triple negative breast cancer (TNBC), announced today ... program. The YEi Start in ... help entrepreneurs grow their business in France ... companies selected to complete an intensive one week immersion in ...
    (Date:2/16/2017)... LOS ANGELES , Feb. 16, 2017 /PRNewswire/ ... CAPR ), a clinical-stage biotechnology company developing first-in-class ... today announced that it has elected to terminate ... to natriuretic peptide receptor agonists, including Cenderitide. ... a strategic move as we prioritize our efforts ...
    (Date:2/16/2017)... N.J. , Feb. 16, 2017  Champions Oncology, ... in the development and sale of advanced technology solutions ... oncology drugs, today announced the addition of new cohorts ... These new models will expand Champions, product line ... head and neck cancer, AML, and non-small cell lung ...
    (Date:2/16/2017)... LAFAYETTE, Indiana (PRWEB) , ... ... ... division of Albany Molecular Research Inc. has further extended its industry leading ... This service offers state-of-the-art cGMP techniques and methods for the ...
    Breaking Biology Technology:
    (Date:1/26/2017)... 2017  Crossmatch, a leading provider of security and ... at combatting fraud, waste and abuse in assistance operations ... Action on Disaster Relief conference in Panama ... agencies and foreign assistance organizations throughout Latin ... are a largely unacknowledged problem in the foreign assistance ...
    (Date:1/23/2017)...  The latest mobile market research from Acuity Market ... The quarterly average price of a biometric smartphone decreased ... 2016.  There are now 120 sub-$150 models on the ... just 28 a year ago at an average price ... Most , Acuity Market Intelligence Principal, "Biometric Smartphones are ...
    (Date:1/18/2017)... 2017 MedNet Solutions , an ... entire spectrum of clinical research, is proud to ... for the organization in terms of corporate growth, ... products and services. The company,s exceptional achievements can ... iMedNet ™ – ...
    Breaking Biology News(10 mins):